Molecular modelling of CYP1A subfamily members based on an alignment with CYP102: Rationalization of CYP1A substrate specificity in terms of active site amino acid residues

Xenobiotica

Volumn 26, Issue 7, 1996, Pages 723-753

  Lewis, D F V ^a   Lake, B G ^b  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b BIBRA INTERNATIONAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIAMINOTOLUENE; 2,5 DIAMINOTOLUENE; 7 ETHOXYCOUMARIN; 7,8 DIHYDROXYBENZO[A]PYRENE; ACETANILIDE; AFLATOXIN B1; AMINO ACID; BENZO[A]PYRENE; CAFFEINE; CYTOCHROME P450; CYTOCHROME P450 ISOENZYME; ESTRADIOL; ETHOXYRESORUFIN; PHENACETIN; UNCLASSIFIED DRUG;

ARTICLE; DRUG METABOLISM; ENZYME SPECIFICITY; HUMAN; MOLECULAR MODEL; XENOBIOTIC METABOLISM;

EID: 0030036211     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.3109/00498259609046745     Document Type: Article

References (101)

1. AGUILAR, F., HUSSAIN, P., and CERUTTI, P., 1993, Aflatoxin B, induces the transversion of G-T in codon 249 of the p53 tumour suppressor gene in human hepatocytes. Proceedings of the National Academy of Sciences, USA, 90, 8546-8590.
2. AYALOGU, E. O., SNELLING, J., LEWIS, D. F. V., TALWAR, S., CLIFFORD, M. N., and IOANNIDES, C., 1995, Selective induction of hepatic CYP1A2 by the oral administration of caffeine to rats. Biochimica et Biophysica Acta, 1272, 89-94.
3. BERESFORD, A. P., 1993, CYP1A1: friend or foe? Drug Metabolism Reviews, 25, 503-517.
4. BERTHOU, F., DREANO, Y., JACQZ-AIGRAIN, E., GUILLOIS, B., and BEAUNE, P. H., 1992, Interspecies variations in caffeine metabolism related to cytochrome P4501A enzymes. Xenobiotica, 22, 671-680.
5. BOYD, G. W., COOMBS, M. M., IOANNIDES, C., LEWIS, D. F. V., SNELLING, J., and TSAKALOF, A., 1995, Species variation in the metabolism of 15,16-dihydro-11-methylcyclopenta[a]phenanthren-17-one to its 3,4-dihydrodiol, the proximate carcinogen. Carcinogenesis, 16, 2351-2355.
6. BURKE, M. D., and MAYER, R. T., 1983, Differential effects of phenobarbitone and 3-methylcholanthrene induction in the hepatic microsomal metabolism and cytochrome P-450 binding of phenoxazone and a homologous series of its n-alkyl ethers (alkoxy resorufins). Chemico-Biological Interactions, 45, 243-258.
7. CHAN, W. K., SUI, Z., and ORTIZ DE MONTELLANO, P. R., 1993, Determinants of protein modification versus heme alkylation: inactivation of cytochrome P4501A1 by 1-ethynylpyrene and phenylacetylene. Chemical Research in Toxicology, 6, 38-45.
8. CHEUNG, Y-L., SNELLING, J., MOHAMMED, N. N. D., GRAY, T. J. B., and IOANNIDES, C., 1996, Interaction with the aromatic hydrocarbon receptor, CYP1A induction and mutagenicity of a series of diaminotoluenes: implications for their carcinogenicity. Toxicology and Applied Pharmacology (in press).
9. COOMBS, M. M., and BHATT, T. S., 1987, Cyclopenta[a]phenanthrenes (Cambridge University Press, Cambridge).
10. CROFTS, F., COSMA, G. N., CURRIE, D., TAIOLI, E., TONIOLO, P., and GARTE, S. J., 1993, A novel CYP1A1 gene polymorphism in African-Americans. Carcinogenesis, 14, 1729-1731.
11. DEGTYARENKO, K. N., and ARCHAKOV, A. I., 1993, Molecular evolution of P450 superfamily and P450-containing mono-oxygenase systems. FEBS Letters, 332, 1-8.
12. DELAFORGE, M., IOANNIDES, C., and PARKE, D. V., 1980, Inhibition of cytochrome P-448 mixed function oxidase activity following administration of O-hydroxyellipticine to rats. Chemico-Biological Interactions, 32, 101-110.
13. EATON, D. L., and GALLAGHER, E. P., 1994, Mechanisms of aflatoxin Carcinogenesis. Annual Review of Pharmacology and Toxicology, 34, 135-172.
14. EDWARDS, R. J., MURRAY, B. P., MURRAY, S., SCHULZ, T., NEUBERT, D., GANT, T. W., THORGEIRSSON, S. S., BOOBIS, A. R., and DAVIES, D. S., 1994, Contribution of CYP1A1 and CYP1A2 to the activation of heterocyclic amines in monkeys and human. Carcinogenesis, 15, 829-836.
15. EDWARDS, R. J., MURRAY, B. P., SINGLETON, A. M., MURRAY, S., DAVIES, D. S., and BOOBIS, A. R., 1993, Identification of the epitope of an anti-peptide antibody which binds to CYP1A2 in many species including man. Biochemical Pharmacology, 46, 213-220.
16. cam monooxygenase can be redesigned to catalyse to regioselective aromatic hydroxylation of diphenylmethane. Chemical Communications, 2761-2762.
17. FUHR, V., STROBL, G., MANAUT, F., ANDERS, E.-M., SORGEL, F., LOPEZ-DE-BRINAS, E., CHU, D. T. W., PERNET, A. G., MAHR, G., SANZ, F., and STAIB, A. H., 1993, Quinolone antibacterial agents: relationship between structure and in vitro inhibition of the human cytochrome P450 isoform CYP1A2. Molecular Pharmacology, 43, 191-199.
18. hm 3 and other inducible bacterial P450 cytochromes: biochemistry and regulation. Annual Review of Pharmacology and Toxicology, 31, 177-203.
19. d changed regio-specificity of acetanilide hydroxylations. Biochemical and Biophysical Research Communications, 160, 669-676.
20. FURUYA, H., SHIMIZU, T., HIRANO, K., HATANO, M., FUJII-KURIYAMA, Y., RAAG, R., and POULOS, T. L., 1989b, Site-directed mutageneses of rat liver cytochrome P-450d: catalytic activities toward benzphetamine and 7-ethoxycoumarin. Biochemistry, 28, 6848-6857.
21. 1. Cancer Research, 54, 101-108.
22. GONZALEZ, F. J. and CRESPI, C. L., and GELBOIN, H. V., 1991, cDNA-expressed human cytochrome P450s: a new age of molecular toxicology and human risk assessment. Mutation Research, 247, 113-127.
23. GONZALEZ, F. J., and GELBOIN, H. V., 1994, Role of human cytochromes P450 in the metabolic activation of chemical carcinogen and toxins. Drug Metabolism Reviews, 26, 165-183.
24. BM P. In Cytochrome P450: Biochemistry, Biophysics and Molecular Biology, edited by M. C. Lechner (Libbey, London), pp. 471-473.
25. GUENGERICH, F. P., 1988, Roles of cytochrome P-450 enzymes in chemical carcinogenesis and cancer chemotherapy. Cancer Research, 48, 2946-2954.
26. GUENGERICH, F. P., 1992a, Human cytochrome P-450 enzymes. Life Sciences, 50, 1471-1478.
27. GUENGERICH, F. P., 1992b, Metabolic activation of carcinogens. Pharmacology and Therapeutics, 54, 17-61.
28. GUENGERICH, F. P., 1993, Cytochrome P450 enzymes. American Scientist, 81, 440-447.
29. GUENGERICH, F. P., 1994, Catalytic selectivity of human cytochrome P450 enzymes: relevance to drug metabolism and toxicity, Toxicology Letters, 70, 133-138.
30. GUENGERICH, F. P., and SHIMADA, T., 1991, Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chemical Research in Toxicology, 4, 391-407.
31. GUENGERICH, F. P., SHIMADA, T., RANEY, K. D., YUN, C.-H., MEYER, D. J., KETTERER, B., HARRIS, T. M., GROOPMAN, J. D., and KADLUBAR, F. F., 1992, Fluctuation of catalytic specificities of human cytochrome P450 and glutathione S-transferase enzymes and relevance to molecular epidemiology. Environmental Health Perspectives, 98, 75-80.
32. HALPERT, J. R., and HE, Y., 1993, Engineering of cytochrome P450 2B1 specificity. Journal of Biological Chemistry, 268, 4453-4457.
33. HALPERT, J. R., GUENGERICH, F. P., BEND, J. R., and CORREIA, M. A., 1994, Selective inhibitors of cytochrome P450. Toxicology and Applied Pharmacology, 125, 163-175.
34. HANKINSON, O., 1995, The aryl hydrocarbon receptor complex. Annual Review of Pharmacology and Toxicology, 35, 307-340.
35. HARVEY, R. G., 1991, Polycyclic Aromatic Hydrocarbons: Chemistry and Carcinogenicity (Cambridge University Press, Cambridge), p. 64.
36. HAYASHI, S. I., WATANABE, J., NAKACHI, K., and KAWAJIRI, K., 1991, Genetic linkage of lung cancer-associated MspI polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P450IA1 gene. Journal of Biochemistry, 110, 407-411.
37. HORN, E. P., TUCKER, M. A., LAMBERT, G., SILVERMAN, D., ZAMETKIN, D., SINHA, R., HARTGE, T., LANDI, M. T., and CAPORASO, N. E., 1995, A study of gender-based cytochrome P4501A2 variability: a possible mechanism for the male excess of bladder cancer. Cancer Epidemiology, Biomarkers and Prevention, 4, 529-533.
38. IOANNIDES, C., and PARKE, D. V., 1990, The cytochrome P4501 gene family of microsomal hemoproteins and their role in the metabolic activation of chemicals. Drug Metabolism Reviews, 22, 1-85.
39. IOANNIDES, C., and PARKE, D. V., 1993, Induction of cytochrome P4501 as an indicator of potential chemical carcinogenesis. Drug Metabolism Reviews, 25, 485-501.
40. JERINA, D. M., MICHAUD, D. P., FELDMAN, R. J., ARMSTRONG, R. N., VYAS, K. P., THAKKER, D. R., YAGI, H., THOMAS, P. E., RYAN, D. E., and LEVIN, W., 1982, Stereochemical modeling of the catalytic site of cytochrome P-450c. In Microsomes, Drug Oxidations and Drug Toxicity, edited by R. Sato and R. Kato (Japan Scientific Societies Press, Tokyo), pp. 195-201.
41. KADLUBAR, F. F., and HAMMONS, G. J., 1987, The role of cytochrome P-450 in the metabolism of chemical carcinogens. In Mammalian Cytochromes P-450, edited by F. P. Guengerich (CRC Press, Boca Raton), vol. 2, 81-130.
42. KAWAJIRI, K., and FUJII-KURIYAMA, Y., 1991, P450 and human cancer. Japanese Journal of Cancer Research, 82, 1325-1335.
43. KAWAJIRI, K., WATANABE, J., and HAYASHI, S.-I., 1992, Roles in genetic polymorphisms of drug metabolising enzymes in humans. Journal of Basic and Clinical Physiology and Pharmacology, 3, 76-77.
44. KORZEKWA, K. R., and JONES, J. P., 1993, Predicting the cytochrome P450 mediated metabolism of xenobiotics. Pharmacogenetics, 3, 1-18.
45. KOYMANS, L., DONNE-OP DEN KELDER, G. M., KOPPELE TE, J. M., and VERMEULEN, N. P. E., 1993, Cytochromes P450: their active-site structure and mechanism of oxidation. Drug Metabolism Reviews, 25, 325-387.
46. KUNZE, K. L., and TRAGER, W. F., 1993, Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chemical Research in Toxicology, 6, 649-656.
47. LAKE, B. G., and LEWIS, D. F. V., 1996, The CYP4 family. In Cytochromes P450: Metabolic and Toxicological Aspects, edited by C. Ioannides (CRC Press, Boca Raton) (in press).
48. LEWIS, D. F. V., 1992, Computer modelling of cytochromes P-450 and their substrates: a rational approach to the prediction of carcinogenicity. Frontiers in Biotransformation, 7, 90-136.
49. LEWIS, D. F. V., 1994, Molecular structural studies in the rationalization of xenobiotic metabolism and toxicity. Toxicology and Ecotoxicology News, 1, 108-112.
50. hm3). Xenobiotica, 25, 333-366.
51. LEWIS, D. F. V., 1995b, Molecular modelling of mammalian cytochromes P450 with specific substrates and inhibitors. In Cytochromes P450: Metabolic and Toxicological Aspects, edited by C. Ioannides (CRC Press, Boca Raton) (in press).
52. LEWIS, D. F. V., 1995c, COMPACT and the importance of frontier orbitals in toxicity, Toxicology Modelling, 1, 85-97.
53. LEWIS, D. F. V., 1995d, The cytochromes P450: ubiquitous enzymes of metabolism, Manufacturing Chemist, 66, 35-37.
54. LEWIS, D. F. V., 1996, Cytochromes P450: Structure, Function and Mechanism (Taylor & Francis, London) (in press).
55. LEWIS, D. F. V., and LAKE, B. G., 1995, Molecular modelling of members of the P4502A subfamily: application to studies of enzyme specificity, Xenobiotica, 25, 585-598.
56. LEWIS, D. F. V., and LAKE, B. G., 1966, The CYP4 family. In Cytochromes P450: Metabolic and Toxicological Aspects, edited by C. Ioannides (CRC Press, Boca Raton) (in press).
57. LEWIS, D. F. V., and MOEREELS, H., 1992, The sequence homologies of cytochromes P450 and active site geometries. Journal of Computer-Aided Molecular Design, 6, 235-252.
58. LEWIS, D. F. V., and PARKE, D. V., 1995, The genotoxicity of benzanthracenes: a quantitative structure-activity study, Mutation Research, 328, 207-214.
59. LEWIS, D. F. V., IOANNIDES, C., and PARKE, D. V., 1986, Molecular dimensions of the substrate binding site of cytochrome P-448. Biochemical Pharmacology, 35, 2179-2185.
60. LEWIS, D. F. V., IOANNIDES, C., and PARKE, D. V., 1987, Structural requirements for substrates of cytochromes P-450 and P-448, Chemico-Biological Interactions, 64, 39-60.
61. LEWIS, D. F. V., MOEREELS, H., LAKE, B. G., IOANNIDES, C., and PARKE, D. V., 1994a, Molecular modelling of enzymes and receptors involved in carcinogenesis: QSARs and COMPACT-3D, Drug Metabolism Reviews, 26, 261-185.
62. LEWIS, D. F. V., IOANNIDES, C., and PARKE, D. V., 1994b, Molecular modelling of cytochrome P4501A1: a putative access channel explains activity differences between structurally related benzo[a]pyrene and benzo[e]pyrene, and 2-acetylaminofluorene and 4-acetylaminofluorene, Toxicology Letters, 71, 235-243.
63. LEWIS, D. F. V., LAKE, B. G., IOANNIDES, C., and PARKE, D. V., 1994c, Inhibition of rat hepatic aryl hydrocarbon hydroxylase activity by a series of 7-hydroxy coumarins : QSAR studies, Xenobiotica, 24, 829-838.
64. LEWIS, D. F. V., IOANNIDES, C., and PARKE, D. V., 1995a, Computer graphics analysis of the interaction of alkoxy methylenedioxygenzenes with cytochromes P4501, Toxicology Letters, 76, 39-45.
65. LEWIS, D. F. V., LAKE, B. G., and PARKE, D. V., 1995b, Molecular orbital-generated quantitative structure-activity relationships in a homologous series of alkoxy resorufins, Xenobiotica, 25, 1355-1369.
66. LEWIS, D. F. V., IOANNIDES, C., and PARKE, D. V., 1995c, Molecular modelling of mammalian cytochromes P450 and evaluation of chemical toxicity and metabolism using COMPACT. In: QSAR and Molecular Modelling, edited by F. Sanz (Prous, Paris) (in press).
67. coh substrate specificity by mutation of a single amino-acid residue, Nature, 339, 632-634.
68. cam to increase the stereospecificity and coupling of aliphatic hydroxylation, Protein Engineering, 6, 207-212.
69. MCMANUS, M. E., BURGESS, W. M., VERONESE, M. E., HUGGETT, A., QUATTROCHI, L. C., and TUKEY, R. H., 1990, Metabolism of 2-acetylaminofluorene and benzo(a)pyrene and activation of food-derived heterocyclic amine mutagens by human cytochrome P-450, Cancer Research, 50, 3367-3376.
70. MARTUCCI, C. P., and FISHMAN, J., 1993, P450 enzymes of estrogen metabolism, Pharmacology and Therapeutics, 57, 237-257.
71. 450cam, Biochemistry, 34, 8982-8988.
72. MORRISON, K. G., OLEKSIAK, M. F., CORNELL, N. W., SOGIN, M. L., and STEGEMAN, J. J., 1995, Identification of cytochrome P-450 1A (CYP1A) genes from two teleost fish, toadfish (Opsanus tau) and scup (Stenotomus chrysops), and phylogenetic analysis of CYP1A genes, Biochemical Journal, 308, 97-104.
73. MUNRO, I. C., KENNEPOHL, E., ERICKSON, R. E., PORTOGHESE, P. S., WAGNER, B. M., EASTERDAY, O. D., and MANLEY, C. H., 1993, Safety assessment of ingested heterocyclic amines: initial report, Regulatory Toxicology and Pharmacology, 17, S1-S109.
74. NEDELCHEVA, V., and GUT, I., 1994, P450 in the rat and man: methods of investigation, substrate specificities and relevance to cancer, Xenobiotica, 24, 1151-1175.
75. NELSON, D. R., and STROBEL, H. W., 1987, Evolution of cytochrome P-450 proteins, Molecular Biology and Evolution, 4, 572-593.
76. NELSON, D. R., KOYMANS, L., KAMATAKI, T., STEGEMAN, J. J., FEYEREISEN, R., WAXMAN, D. J., WATERMAN, M. R., GOTOH, O., COON, M. J., GUNSALUS, I. C. and NEBERT, D. W., 1996, CYP450 Superfamily: update on new sequences, gene mapping, accession numbers and nomenclature, Pharmacogenetics, 6, 1-42.
77. NELSON, D. R., KAMATAKI, T., WAXMAN, D. J., GUENGERICH, F. P., ESTABROOK, R. W., FEYEREISEN, R., GONZALEZ, F. J., COON, M. J., GUNSALUS, I. C., GOTOH, O., OKUDA, K., and NEBERT, D. W., 1993, The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes and nomenclature, DNA and Cell Biology, 12, 1-51.
78. NERURKAR, P. V., PARK, S. S., THOMAS, P. E., NIMS, R. W., and LUBET, R. A., 1993, Methoxyresorufin and benzyloxyresorufin: substrates preferentially metabolized by cytochromes P4501A2 and 2B, respectively, in the rat and mouse, Biochemical Pharmacology, 46, 933-943.
79. PARKE, D. V., IOANNIDES, C., IWASAKI, K., and LEWIS, D. F. V., 1985, Microsomal enzymes and toxicity. In Microsomes and Drug Oxidations, edited by A. R. Boobis, J. Caldwell, F. De Matteis and C. R. Elcombe (Taylor & Francis, London), pp. 402-413.
80. cam: T185F mutant increases coupling and abolishes 3-hydroxynorcamphor product, Protein Science, 2, 357-365.
81. PHILLIPS, D. H., and GROVER, P. L., 1994, Polycyclic hydrocarbon activation: bay regions and beyond, Drug Metabolism Reviews, 26, 443-467.
82. PORTER, T. D., and COON, M. J., 1991, Cytochromes P-450: multiplicity of isoforms, substrates and catalytic and regulatory mechanisms, Journal of Biological Chemistry, 266, 13469-13472.
83. RAVICHANDRAN, K. G., BODDUPALLI, S. S., HASEMANN, C. A., PETERSON, J. A., and DEISENHOFER, J., 1993, Crystal structure of hemoprotein domain of P450BM-3, a prototype for microsomal P450s, Science, 261, 731-736.
84. SANZ, F., LOPEZ-DE-BRINAS, E., RODRIGUEZ, J., and MANAUT, F., 1994a, Theoretical study on the metabolism of caffeine by cytochrome P-4501A2 and its inhibition, Quantitative Structure-Activity Relationships, 13, 281-284.
85. SANZ, F., LOZANO, J. J., LOPEZ-DE-BRINAS, E., DE-LA-TORRE, R., and MANAUT, F., 1994b, Carcinogenic activation of cooked food heterocyclic amines by cytochrome P450 1A2. A theoretical study. In Cytochrome P450. 8th International Conference, edited by M. C. Lechner (John Libbey, Paris), pp. 575-578.
86. SESARDIC, D., BOOBIS, A. R., MURRAY, B. P., MURRAY, S., SEGURA, J., DE LA TORRE, R., and DAVIES, D. S., 1990, Furafylline is a potent and selective inhibitor of cytochrome P4501A2 in man, British Journal of Clinical Pharmacology, 29, 651-663.
87. SHIMADA, T., IWASAKI, M., MARTIN, M. V., and GUENGERICH, F. P., 1989, Human liver microsomal cytochrome P450 enzymes involved in the bioactivation of procarcinogens detected by umu gene response in Salmonella Tryphimurium TA 1535/pSK1002, Cancer Research, 49, 3218-3228.
88. SHIMADA, T., YAMAZAKI, H., MIMURA, M., INUI, Y., and GUENGERICH, F. P., 1994, Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals, Journal of Pharmacology and Experimental Therapeutics, 270, 414-423.
89. 319 mutants of cytochrome P4501A2 remarkably enhance homolytic O-O cleavage of alkyl hydroperoxides, Journal of Biological Chemistry, 269, 13296-13304.
90. SMITH, D. A., ABEL, S. M., HYLAND, R., and JONES, B. C., 1996, Cytochromes P450: selectivity and measurement in vivo, Xenobiotica, 26 (in press).
91. SNYDERWINE, E. G., BUONARATI, M. H., FELTON, J. S., and TURTLETAUB, K. W., 1993, Metabolism of the food-derived mutagen/carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in nonhuman primates, Carcinogenesis, 14, 2517-2522.
92. SOUCEK, P., and GUT, I., 1992, Cytochromes P-450 in rats: structures, functions, properties and relevant human forms, Xenobiotica, 22, 83-103.
93. SPATZENEGGER, M., and JAEGER, W., 1995, Clinical importance of hepatic cytochrome P450 in drug metabolism, Drug Metabolism Reviews, 27, 397-417.
94. TSANG, W. S., and GRIFFIN, G. W., 1979, Metabolic Activation of Polynuclear Aromatic Hydrocarbons (Pergamon, Oxford), p. 97.
95. TUCK, S. F., HIROYA, K., SHIMIZU, T., HATANO, M., and ORTIZ DE MONTELLANO, P. R., 1993, The cytochrome P4501A2 active site: topology and perturbations caused by glutamic acid-318 and threonine-319 mutations, Biochemistry, 32, 2548-2533.
96. TUCK, S. F., PETERSON, J. A., and ORTIZ DE MONTELLANO, P. R., 1992, Active site topologies of bacterial cytochromes P450101 (P450cam), P450108 (P450terp) and P450102 (P450BM-3): in situ rearrangement of their phenyl-iron complexes, Journal of Biological Chemistry, 267, 5614-5620.
97. WAKABAYASHI, K., NAGAO, M., ESUMI, H., and SUGIMURA, T., 1992, Food-derived mutagens and carcinogens, Cancer Research, 52 (suppl.), 20925-20985.
98. YANG, S. K., 1988, Stereoselectivity of cytochrome P-450 isozymes and epoxide hydrolase in the metabolism of polycyclic aromatic hydrocarbons, Biochemical Pharmacology, 37, 61-70.
99. YUN, C.-H., HAMMONS, G. J., JONES, G., MARTIN, M. V., HOPKINS, N. E., ALWORTH, W. L., and GUENGERICH, F. P., 1992, Modification of cytochrome P4501A2 enzymes by the mechanism-based inactivator 2-ethynylnaphthalene and the photoaffinity label 4-azidobiphenyl, Biochemistry, 31, 10556-10563.
100. ZHAO, K., MURRAY, S., DAVIES, D. S., BOOBIS, A. R., and GOODERHAM, N. J., 1994, Metabolism of the food derived mutagen and carcinogen 2-amino-1-methyl-6-phenylimidazo (4,5-b) pyridine (PhIP) by human liver microsomes, Carcinogenesis, 15, 1285-1288.
101. ZVELEBIL, M. J. J. M., WOLF, C. R., and STERNBERG, M. J. E., 1991, A predicted three-dimensional structure of human cytochrome P450: implications for substrate specificity, Protein Engineering, 4, 271-281.